Under construction – not a live service

Skip to content

Frontlight Research

Trial site

Lucas Research, Inc.

Morehead City, North Carolina 28557, United StatesNot linked to an institution yet

16running trials
18closed trials

The trials here

What the 34 trials at this site are about, from their registry records.

Conditions: Obesity17 trials
Type 2 diabetes16 trials
Fatty liver disease (MASLD/MASH)5 trials
Type 1 diabetes4 trials
Chronic kidney disease3 trials
Liver cirrhosis2 trials
Cushing's syndrome1 trial
Familial hypercholesterolaemia1 trial
High blood pressure1 trial
Phase: Phase 219 trials
Phase 313 trials
Phase 11 trial
Phase 41 trial
Status: Completed15 trials
Recruiting10 trials
Active, not recruiting4 trials
Not yet recruiting2 trials
Terminated2 trials
Withdrawn1 trial
Lead sponsor: Eli Lilly and Company16 trials
Boehringer Ingelheim7 trials
Carmot Therapeutics, Inc.2 trials
Biomea Fusion Inc.1 trial
Gilead Sciences1 trial
and 7 more

Running trials

Not yet recruiting
A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes
NCT07890376· Phase 2· Eli Lilly and Company· Source
Contact: Kathryn Lucas (principal investigator)
Not yet recruiting
SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight
NCT07850050· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)
NCT07817875· Phase 3· Eli Lilly and Company· Source
Contact: Kathryn Lucas (principal investigator)
Recruiting
Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus
NCT07527650· Phase 2· Hanmi Pharmaceutical Company Limited· Source
Contact: Kathryn Jean Lucas (principal investigator)
Recruiting
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
NCT07589608· Phase 2· Eli Lilly and Company· Source
Contact: Kathryn Lucas (principal investigator)
Recruiting
A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)
NCT07325526· Phase 2· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)
NCT07296484· Phase 2· Sparrow Pharmaceuticals· Source
Contact: Christina Manager
Recruiting
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Active, not recruiting
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
NCT06914895· Phase 3· Eli Lilly and Company· Source
Recruiting
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
NCT06897475· Phase 2· Eli Lilly and Company· Source
Contact: Kathryn Lucas (principal investigator)
Recruiting
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
NCT06672549· Phase 3· Eli Lilly and Company· Source
Contact: Kathryn Lucas (principal investigator)
Recruiting
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
NCT06672939· Phase 3· Eli Lilly and Company· Source
Recruiting
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
NCT06143956· Phase 2· Eli Lilly and Company· Source
Contact: Kathryn Lucas (principal investigator)
Recruiting
A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes
NCT05762107· Phase 2· Zucara Therapeutics Inc.· Source
Contact: Mari Dunn
Active, not recruiting
A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes
NCT05433584· Phase 4· Eli Lilly and Company· Source
Active, not recruiting
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
NCT04849728· Phase 3· Inventiva Pharma· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Obesity7 recruiting
Type 2 diabetes6 recruiting
Cushing's syndrome1 recruiting
Fatty liver disease (MASLD/MASH)1 recruiting
High blood pressure1 recruiting
Liver cirrhosis1 recruiting
Type 1 diabetes1 recruiting

Closed trials

Completed
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease
NCT06926660· Phase 2· Boehringer Ingelheim· Source
Terminated
A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes
NCT07030868· Phase 2· Eli Lilly and Company· Source
Completed
A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight
NCT06683508· Phase 2· Eli Lilly and Company· Source
Withdrawn
Efficacy and Safety of Volenrelaxin in Adults With Chronic Kidney Disease
NCT06598631· Phase 2· Eli Lilly and Company· Source
Completed
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
NCT06603571· Phase 2· Eli Lilly and Company· Source
Completed
A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity
NCT06525935· Phase 2· Carmot Therapeutics, Inc.· Source
Completed
Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies
NCT06005597· Phase 3· NewAmsterdam Pharma· Source
Completed
Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus
NCT06152042· Phase 2· Biomea Fusion Inc.· Source
Completed
A Study of CT-868 in Type 1 Diabetes Mellitus
NCT06062069· Phase 2· Carmot Therapeutics, Inc.· Source
Completed
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
NCT06066528· Phase 3· Boehringer Ingelheim· Source
Completed
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight
NCT06066515· Phase 3· Boehringer Ingelheim· Source
Completed
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
NCT06045221· Phase 3· Eli Lilly and Company· Source
Completed
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
NCT05803421· Phase 3· Eli Lilly and Company· Source
Terminated
A Study to Evaluate How Ontamalimab Works and Assess Its Safety and Tolerability in People With Nonalcoholic Steatohepatitis With Fibrosis Stages 1 to 4
NCT07052682· Phase 1· Takeda· Source
Completed
Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis
NCT05327127· Phase 2· Kowa Research Institute, Inc.· Source
Completed
A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time
NCT05362058· Phase 3· Eli Lilly and Company· Source
Completed
Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
NCT04971785· Phase 2· Gilead Sciences· Source
Completed
A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)
NCT04771273· Phase 2· Boehringer Ingelheim· Source

Site data: ClinicalTrials.govUpdated 12 Nov 2026

Report an error